Budapest – September 22, 2026 -- South Korean biopharmaceutical company PharmaResearch officially launched its REJURAN portfolio of polynucleotide (PN)-based skin boosters in Hungary, marking its latest expansion move in Europe's aesthetic medicine market.

Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.

Milan – September 21, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.

Taipei – September 21, 2026 -- Merry Life Biomedical has advanced TML-6, a Taiwan-developed oral therapy for early Alzheimer's disease, into a global Phase 2 trial spanning 20 clinical sites across Taiwan, Sweden, and the United States, targeting approximately 210 participants.

Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Pune, India – September 21, 2026 -- The global pharmaceutical logistics market is set to nearly double from approximately $100.0 billion in 2025 to $194.0 billion by 2034, expanding at a 7.7% compound annual growth rate, according to a new report from Maximize Market Research.

Houston – – September 21, 2026 -- Eli Lilly and Company (NYSE: LLY) has broken ground on a $6.5 billion manufacturing site in Houston, Texas, that will produce active pharmaceutical ingredients for Foundayo (orforglipron), the company's first synthetic oral GLP-1 medicine for weight management.

Warren, N.J. – September 21, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.

Princeton – September 21, 2026 -- Made Scientific, Inc. has acquired an 85,000 sq. ft. clinical-to-commercial cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience, closing the transaction on September 18, 2026. The purchase expands the company's U.S. East Coast footprint to approximately 145,000 sq. ft. and 15 qualified GMP manufacturing suites across New Jersey and Pennsylvania.

Waltham, Mass. – September 21, 2026 -- The U.S. Food and Drug Administration has approved Mercy BioAnalytics' Investigational Device Exemption application for its Evident Ovarian Cancer Screening Test, clearing the way for the company's pivotal SOARA Clinical Validation Study pending Institutional Review Board sign-off.